Department of Immunoregulation, Institute of Medical Science.
Animal Research Center, and.
J Clin Invest. 2020 Nov 2;130(11):6124-6140. doi: 10.1172/JCI122732.
Epstein-Barr virus-induced gene 3 (EBI3) is a subunit common to IL-27, IL-35, and IL-39. Here, we explore an intracellular role of EBI3 that is independent of its function in cytokines. EBI3-deficient naive CD4+ T cells had reduced IFN-γ production and failed to induce T cell-dependent colitis in mice. Similarly reduced IFN-γ production was observed in vitro in EBI3-deficient CD4+ T cells differentiated under pathogenic Th17 polarizing conditions with IL-23. This is because the induction of expression of one of the IL-23 receptor (IL-23R) subunits, IL-23Rα, but not another IL-23R subunit, IL-12Rβ1, was selectively decreased at the protein level, but not the mRNA level. EBI3 augmented IL-23Rα expression via binding to the chaperone molecule calnexin and to IL-23Rα in a peptide-dependent manner, but not a glycan-dependent manner. Indeed, EBI3 failed to augment IL-23Rα expression in the absence of endogenous calnexin. Moreover, EBI3 poorly augmented the expression of G149R, an IL-23Rα variant that protects against the development of human colitis, because binding of EBI3 to the variant was reduced. Taken together with the result that EBI3 expression is inducible in T cells, the present results suggest that EBI3 plays a critical role in augmenting IL-23Rα protein expression via calnexin under inflammatory conditions.
EB 病毒诱导基因 3(EBI3)是 IL-27、IL-35 和 IL-39 的共同亚基。在这里,我们探讨了 EBI3 的一种细胞内作用,该作用独立于其在细胞因子中的功能。EBI3 缺陷的幼稚 CD4+T 细胞 IFN-γ 产生减少,并且在小鼠中无法诱导 T 细胞依赖性结肠炎。同样,在体外,在致病性 Th17 极化条件下用 IL-23 分化的 EBI3 缺陷型 CD4+T 细胞中也观察到 IFN-γ 产生减少。这是因为 IL-23 受体(IL-23R)亚基之一,即 IL-23Rα的表达诱导,但不是另一个 IL-23R 亚基,IL-12Rβ1 的表达诱导,在蛋白质水平而不是 mRNA 水平选择性降低。EBI3 通过与伴侣分子 calnexin 结合以及以肽依赖性方式与 IL-23Rα 结合来增强 IL-23Rα 的表达,但不是以糖依赖性方式。事实上,EBI3 在没有内源性 calnexin 的情况下无法增强 IL-23Rα 的表达。此外,EBI3 对 G149R 的表达增强作用不佳,G149R 是一种 IL-23Rα 变体,可防止人类结肠炎的发展,因为 EBI3 与变体的结合减少了。鉴于 T 细胞中 EBI3 表达可诱导的结果,本研究结果表明,EBI3 在炎症条件下通过 calnexin 发挥关键作用,增强 IL-23Rα 蛋白表达。
J Clin Invest. 2020-11-2
Proc Natl Acad Sci U S A. 2002-12-24
Gastroenterology. 2011-8-4
Proc Natl Acad Sci U S A. 2017-1-31
Eur J Immunol. 2008-5
J Immunol. 2024-10-15
J Immunol. 2024-10-15
Front Immunol. 2020
Immunity. 2019-4-16
Mol Immunol. 2019-1-17
Eur J Immunol. 2016-6
Immunity. 2016-2-16